{
    "symbol": "TCDA",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 21:00:34",
    "content": " Forward-looking statements include our anticipated activities related to the VALOR-CKD renal outcomes clinical trial, including anticipated endpoint events, accruals and the estimated timing for receipt of top line data as well as our expectations regarding our financial runway. As of today, the 1480 subjects who were randomized in the VALOR-CKD trial at an average treatment duration of approximately 26.5 months, and the trial had accrued 281 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease or greater than or equal to 40% reduction in eGFR."
}